You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePrazepam
Accession NumberDB01588
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionPrazepam is a benzodiazepine that is used in the treatment of anxiety disorders. It is a schedule IV drug in the U.S.
Structure
Thumb
Synonyms
Centrax
Prazepamum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CentraxNot Available
DemetrinNot Available
LysanxiaNot Available
SedapranNot Available
TrepidanNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQ30VCC064M
CAS number2955-38-6
WeightAverage: 324.804
Monoisotopic: 324.102940883
Chemical FormulaC19H17ClN2O
InChI KeyInChIKey=MWQCHHACWWAQLJ-UHFFFAOYSA-N
InChI
InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
IUPAC Name
7-chloro-1-(cyclopropylmethyl)-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of anxiety disorders.
PharmacodynamicsPrazepam is a benzodiazepine derivative drug. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Benzodiazepines may be habit-forming (causing mental or physical dependence), especially when taken for a long time or in high doses.
Mechanism of actionPrazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life36-200 hours
ClearanceNot Available
ToxicitySymptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9821
Blood Brain Barrier+0.9934
Caco-2 permeable+0.6922
P-glycoprotein substrateSubstrate0.6631
P-glycoprotein inhibitor IInhibitor0.7452
P-glycoprotein inhibitor IIInhibitor0.6438
Renal organic cation transporterInhibitor0.6625
CYP450 2C9 substrateNon-substrate0.7317
CYP450 2D6 substrateNon-substrate0.8332
CYP450 3A4 substrateSubstrate0.7471
CYP450 1A2 substrateInhibitor0.861
CYP450 2C9 inhibitorInhibitor0.5153
CYP450 2D6 inhibitorNon-inhibitor0.7477
CYP450 2C19 inhibitorInhibitor0.7793
CYP450 3A4 inhibitorInhibitor0.6455
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7974
Ames testNon AMES toxic0.8623
CarcinogenicityNon-carcinogens0.8138
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8779 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9819
hERG inhibition (predictor II)Non-inhibitor0.5471
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Doral 15 mg tablet3.41USD tablet
Doral 7.5 mg tablet3.37USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point145-146 °CPhysProp
logP3.73HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00399 mg/mLALOGPS
logP3.68ALOGPS
logP3.86ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)3.06ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.67 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity91.75 m3·mol-1ChemAxon
Polarizability34.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00r5-3391000000-0113e86cca51d223d412View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05BA11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Prazepam is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Prazepam is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Prazepam is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Prazepam is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Prazepam.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Prazepam.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Prazepam.
AminophyllineThe therapeutic efficacy of Prazepam can be decreased when used in combination with Aminophylline.
AmiodaroneThe metabolism of Prazepam can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Prazepam is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Prazepam is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Prazepam.
AmoxapineThe risk or severity of adverse effects can be increased when Prazepam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Prazepam is combined with Amperozide.
AprepitantThe serum concentration of Prazepam can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Prazepam.
ArticaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Prazepam is combined with Asenapine.
AtazanavirThe metabolism of Prazepam can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Prazepam can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Azaperone.
AzelastinePrazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Prazepam.
BaclofenThe risk or severity of adverse effects can be increased when Prazepam is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Prazepam.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Prazepam.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Prazepam is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Prazepam can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Prazepam can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Prazepam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Prazepam can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Prazepam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.
BrimonidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Prazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Prazepam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Prazepam.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Prazepam.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Prazepam.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Prazepam.
ButacaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Prazepam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Prazepam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Prazepam.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Prazepam.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Prazepam.
CarbinoxamineThe risk or severity of adverse effects can be increased when Prazepam is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Prazepam.
CarisoprodolThe risk or severity of adverse effects can be increased when Prazepam is combined with Carisoprodol.
CeritinibThe serum concentration of Prazepam can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Prazepam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Prazepam.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Prazepam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Prazepam.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Prazepam.
ChlorphenamineThe risk or severity of adverse effects can be increased when Prazepam is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Prazepam.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Prazepam.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Prazepam.
CitalopramThe risk or severity of adverse effects can be increased when Prazepam is combined with Citalopram.
ClarithromycinThe metabolism of Prazepam can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Prazepam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Prazepam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Prazepam is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Prazepam is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Prazepam.
ClotrimazoleThe metabolism of Prazepam can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Prazepam.
CobicistatThe metabolism of Prazepam can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Prazepam.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Prazepam.
ConivaptanThe serum concentration of Prazepam can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Prazepam can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Prazepam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prazepam.
CyclosporineThe metabolism of Prazepam can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Prazepam is combined with Cyproheptadine.
DabrafenibThe serum concentration of Prazepam can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Prazepam is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prazepam.
DapoxetineThe risk or severity of adverse effects can be increased when Prazepam is combined with Dapoxetine.
DarunavirThe metabolism of Prazepam can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Prazepam can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Prazepam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Prazepam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Prazepam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Prazepam.
DesipramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Prazepam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Detomidine.
DexamethasoneThe serum concentration of Prazepam can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Prazepam.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Prazepam.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Prazepam.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Prazepam.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Prazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Prazepam is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Prazepam.
DihydroergotamineThe metabolism of Prazepam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Prazepam.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Prazepam.
DiltiazemThe metabolism of Prazepam can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Prazepam is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Prazepam.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Prazepam.
DoramectinThe risk or severity of adverse effects can be increased when Prazepam is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Prazepam is combined with Doxepin.
DoxycyclineThe metabolism of Prazepam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.
DoxylamineThe risk or severity of adverse effects can be increased when Prazepam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Prazepam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Prazepam.
DronedaroneThe metabolism of Prazepam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Prazepam.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Prazepam.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Prazepam.
DyphyllineThe therapeutic efficacy of Prazepam can be decreased when used in combination with Dyphylline.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Prazepam.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Prazepam is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Prazepam can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Prazepam is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Prazepam.
EntacaponeThe risk or severity of adverse effects can be increased when Prazepam is combined with Entacapone.
EnzalutamideThe serum concentration of Prazepam can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Prazepam can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Prazepam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Prazepam can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Prazepam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Prazepam.
EthanolPrazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Prazepam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prazepam.
EthosuximideThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Prazepam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Prazepam.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Prazepam.
EtidocaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Prazepam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Prazepam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Prazepam.
EtoperidoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Prazepam.
EtravirineThe serum concentration of Prazepam can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Prazepam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Prazepam is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Prazepam.
FenfluramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Prazepam.
FexofenadineThe risk or severity of adverse effects can be increased when Prazepam is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Prazepam is combined with Flibanserin.
FluconazoleThe metabolism of Prazepam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Prazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Prazepam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Prazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Prazepam.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Prazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Prazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Prazepam can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Prazepam can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Prazepam can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Prazepam.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Prazepam.
FospropofolThe risk or severity of adverse effects can be increased when Prazepam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Prazepam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Prazepam.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Prazepam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Prazepam.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Prazepam.
GuanfacineThe risk or severity of adverse effects can be increased when Prazepam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Prazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Prazepam.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Prazepam.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Prazepam.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Prazepam.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Prazepam.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Prazepam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.
HydroxyzineThe risk or severity of adverse effects can be increased when Prazepam is combined with Hydroxyzine.
IdelalisibThe serum concentration of Prazepam can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Iloperidone.
ImatinibThe metabolism of Prazepam can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Prazepam is combined with Indalpine.
IndinavirThe metabolism of Prazepam can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Prazepam can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Prazepam.
IsradipineThe metabolism of Prazepam can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Prazepam can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Prazepam can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Prazepam.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Prazepam.
KetobemidoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Ketobemidone.
KetoconazoleThe metabolism of Prazepam can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Prazepam is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Prazepam is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Prazepam.
LevocabastineThe risk or severity of adverse effects can be increased when Prazepam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Prazepam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Prazepam is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Prazepam.
LevomilnacipranThe risk or severity of adverse effects can be increased when Prazepam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Prazepam.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Prazepam.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Prazepam.
LofentanilThe risk or severity of adverse effects can be increased when Prazepam is combined with Lofentanil.
LopinavirThe metabolism of Prazepam can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Prazepam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Prazepam.
LovastatinThe metabolism of Prazepam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Prazepam.
Lu AA21004The risk or severity of adverse effects can be increased when Prazepam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Prazepam can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Prazepam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Prazepam is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Prazepam is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Prazepam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Prazepam.
MelperoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Prazepam.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prazepam.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Prazepam.
MetaxaloneThe risk or severity of adverse effects can be increased when Prazepam is combined with Metaxalone.
MethadonePrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Prazepam.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Prazepam.
MethapyrileneThe risk or severity of adverse effects can be increased when Prazepam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Prazepam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Prazepam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Prazepam.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Prazepam.
MethsuximideThe risk or severity of adverse effects can be increased when Prazepam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Prazepam.
MetyrosinePrazepam may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Prazepam.
MifepristoneThe metabolism of Prazepam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Prazepam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prazepam.
MirtazapinePrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Prazepam.
MitotaneThe serum concentration of Prazepam can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Prazepam can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Prazepam.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Prazepam.
NabiloneThe risk or severity of adverse effects can be increased when Prazepam is combined with Nabilone.
NafcillinThe serum concentration of Prazepam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Prazepam.
NefazodoneThe metabolism of Prazepam can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Prazepam can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Prazepam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Prazepam can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Prazepam can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Prazepam is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Prazepam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Prazepam.
OlaparibThe metabolism of Prazepam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Prazepam is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Prazepam.
OpiumThe risk or severity of adverse effects can be increased when Prazepam is combined with Opium.
OrphenadrinePrazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Prazepam.
OsanetantThe risk or severity of adverse effects can be increased when Prazepam is combined with Osanetant.
OsimertinibThe serum concentration of Prazepam can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Prazepam.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Prazepam.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Prazepam.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Prazepam.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Prazepam.
PalbociclibThe serum concentration of Prazepam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Prazepam.
ParaldehydePrazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Prazepam.
ParoxetineThe risk or severity of adverse effects can be increased when Prazepam is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Prazepam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Prazepam.
PerampanelThe risk or severity of adverse effects can be increased when Prazepam is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Prazepam is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Prazepam.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Prazepam.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Prazepam.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Prazepam is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Prazepam.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Prazepam.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Prazepam.
PipamperoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Prazepam is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Prazepam is combined with Pomalidomide.
PosaconazoleThe metabolism of Prazepam can be decreased when combined with Posaconazole.
PramipexolePrazepam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Pramocaine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Prazepam.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Prazepam.
PrimidoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Prazepam.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Prazepam.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Prazepam.
PromethazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Prazepam.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Prazepam.
PropoxycaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Prazepam is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Prazepam is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Prazepam.
RamelteonThe risk or severity of adverse effects can be increased when Prazepam is combined with Ramelteon.
RanolazineThe metabolism of Prazepam can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Prazepam.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Prazepam.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Prazepam.
RifabutinThe metabolism of Prazepam can be increased when combined with Rifabutin.
RifampicinThe metabolism of Prazepam can be increased when combined with Rifampicin.
RifapentineThe metabolism of Prazepam can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Prazepam.
RitonavirThe metabolism of Prazepam can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Romifidine.
RopinirolePrazepam may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Prazepam.
RotigotinePrazepam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Prazepam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Prazepam is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Prazepam can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Prazepam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prazepam.
SertindoleThe risk or severity of adverse effects can be increased when Prazepam is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Prazepam is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Prazepam.
SildenafilThe metabolism of Prazepam can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Prazepam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Prazepam can be increased when it is combined with Simeprevir.
Sodium oxybatePrazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Prazepam.
St. John's WortThe serum concentration of Prazepam can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Prazepam is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Prazepam.
SulfisoxazoleThe metabolism of Prazepam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Prazepam.
SuvorexantThe risk or severity of adverse effects can be increased when Prazepam is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Prazepam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Prazepam is combined with Tasimelteon.
TeduglutideThe serum concentration of Prazepam can be increased when it is combined with Teduglutide.
TelaprevirThe metabolism of Prazepam can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Prazepam can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Prazepam.
TetrabenazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetrodotoxin.
ThalidomidePrazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Prazepam.
TheophyllineThe therapeutic efficacy of Prazepam can be decreased when used in combination with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Prazepam.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Prazepam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Prazepam.
ThiothixeneThe risk or severity of adverse effects can be increased when Prazepam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Prazepam is combined with Tiagabine.
TiclopidineThe metabolism of Prazepam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Prazepam is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Tizanidine.
TocilizumabThe serum concentration of Prazepam can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Prazepam is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Prazepam is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Prazepam.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Prazepam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prazepam.
TrazodoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Prazepam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Prazepam.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Prazepam.
TrimipramineThe risk or severity of adverse effects can be increased when Prazepam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Prazepam.
VenlafaxineThe metabolism of Prazepam can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Prazepam can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Prazepam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Vilazodone.
VoriconazoleThe metabolism of Prazepam can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Prazepam is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Prazepam is combined with Xylazine.
YohimbineThe therapeutic efficacy of Prazepam can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Prazepam.
ZiconotideThe risk or severity of adverse effects can be increased when Prazepam is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Prazepam is combined with Zimelidine.
ZiprasidoneThe metabolism of Prazepam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Prazepam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Prazepam.
ZonisamideThe risk or severity of adverse effects can be increased when Prazepam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Prazepam.
ZotepineThe risk or severity of adverse effects can be increased when Prazepam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Prazepam is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid taking with grapefruit juice.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Amin J, Brooks-Kayal A, Weiss DS: Two tyrosine residues on the alpha subunit are crucial for benzodiazepine binding and allosteric modulation of gamma-aminobutyric acidA receptors. Mol Pharmacol. 1997 May;51(5):833-41. [PubMed:9145922 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 09:29 / Updated on August 17, 2016 12:23